Transcatheter aortic valve replacement as an alternative to open surgical repair is rapidly becoming more used in high-risk patients with aortic stenosis. Transcatheter aortic valve replacement offers the benefit of being much less invasive than traditional surgical repair and has evolved as a therapeutic option for patients with prohibitive surgical risk or those deemed surgically inoperable. Nevertheless, despite its potential to mitigate risk in this frail population, it comes with its own unique set of complications. Technological advancements in valve structure, function, and delivery have and continue to attempt to minimize these risks. This review aims to summarize current advancements in transcatheter aortic valve replacement technology while also introducing areas of future direction in this exciting new field.
RogerV.L., GoA.S., Lloyd-JonesD.M.Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation.2012; 125: e2–e220.
2.
VincentG.K., VelkoffV.A.The Next Four Decades, The Older Population in the United States: 2010 to 2050.U.S. Census Bureau: U.S. Department of Commerce; 2010. Available at: https://www.census.gov/prod/2010pubs/p25–1138.pdf. Accessed February 10, 2015.
3.
ShahP.K.Should severe aortic stenosis be operated on before symptom onset? Severe aortic stenosis should not be operated on before symptom onset. Circulation.2012; 126: 118–125.
4.
BonowR.O., CarabelloB.A., ChatterjeeK.2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol.2008; 52: e1–e142.
5.
HolmesD.R.Jr., MackM.J., KaulS.2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collabration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Thorac Cardiovasc Surg.2012; 144: e29–e84.
6.
ThouraniV.H., AilawadiG., SzetoW.Y.Outcomes of surgical aortic valve replacement in high-risk patients: a multiinstitutional study. Ann Thorac Surg.2011; 91: 49–56.
7.
LeonM.B., SmithC.R., MackM.Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med.2010; 363: 1597–1607.
8.
CribierA., EltchaninoffH., BashA.Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation.2002; 106: 3006–3008.
9.
MakkarR.R., FontanaG.P., JilaihawiH.Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med.2012; 366: 1696–1704.
10.
OstenM.D., FeindelC., GreutmannM.Transcatheter aortic valve implantation for high risk patients with severe aortic stenosis using the Edwards Sapien balloon-expandable bioprosthesis: a single centre study with immediate and medium-term outcomes. Catheter Cardiovasc Interv.2010; 75: 475–485.
11.
SmithC.R., LeonM.B., MackM.J.Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med.2011; 364: 2187–2198.
12.
TamburinoC., CapodannoD., RamondoA.Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation.2011; 123: 299–308.
13.
Abdel-WahabM., ZahnR., HorackM.Aortic regurgitation after trans-catheter aortic valve implantation: incidence and early outcome. Results from the German transcatheter aortic valve interventions registry. Heart.2011; 97: 899–906.
14.
LudmanP.F., MoatN., de BelderM.A.Transcatheter aortic valve implantation in the United Kingdom: temporal trends, predictors of outcome, and 6-year follow-up: a report from the UK Transcatheter Aortic Valve Implantation (TAVI) Registry, 2007 to 2012. Circulation.2015; 131: 1181–1190.
15.
BabaliarosV.C., JunagadhwallaZ., LerakisS.Use of balloon aortic valvuloplasty to size the aortic annulus before implantation of a balloon-expandable transcatheter heart valve. JACC Cardiovasc Interv.2010; 3: 114–118.
16.
PatsalisP.C., Al-RashidF., NeumannT.Preparatory balloon aortic valvuloplasty during transcatheter aortic valve implantation for improved valve sizing. JACC Cardiovasc Interv.2013; 6: 965–971.
17.
MussardoM., LatibA., ChieffoA.Periprocedural and short-term outcomes of transfemoral transcatheter aortic valve implantation with the Sapien XT as compared with the Edwards Sapien valve. JACC Cardiovasc Interv.2011; 4: 743–750.
18.
Abdel-WahabM., MehilliJ., FrerkerC.Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement: the CHOICE randomized clinical trial. JAMA.2014; 311: 1503–1514.
19.
Rodés-CabauJ.Transcatheter aortic valve implantation: current and future approaches. Nat Rev Cardiol.2012; 9: 15–29.
20.
JilaihawiH., ChakravartyT., WeissR.E., FontanaG.P., ForresterJ., MakkarR.R.Meta-analysis of complications in aortic valve replacement: comparison of Medtronic-Corevalve, Edwards-Sapien and surgical aortic valve replacement in 8,536 patients. Catheter Cardiovasc Interv.2012; 80: 128–138.
21.
AdamsD.H., PopmaJ.J., ReardonM.J.Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med.2014; 371: 967–968.
22.
UrenaM., WebbJ.G., TamburinoC.Permanent pacemaker implantation after transcatheter aortic valve implantation: impact on late clinical outcomes and left ventricular function. Circulation.2014; 129: 1233–1243.
23.
BabaliarosV., DevireddyC., LerakisS.Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. JACC Cardiovasc Interv.2014; 7: 898–904.
24.
MackM.J., BrennanJ.M., BrindisR.Outcomes following transcatheter aortic valve replacement in the United States. JAMA.2013; 310: 2069–2077.
25.
ThouraniV.H., GunterR.L., NeravetlaS.Use of transaortic, transapical, and transcarotid transcatheter aortic valve replacement in inoperable patients. Ann Thorac Surg.2013; 96: 1349–1357.
26.
GreenbaumA.B., O'NeillW.W., PaoneG.Caval-aortic access to allow transcatheter aortic valve replacement in otherwise ineligible patients: initial human experience. J Am Coll Cardiol.2014; 63(25 Pt A): 2795–2804.
27.
LeonM.B., GadaH., FontanaG.P.Challenges and future opportunities for transcatheter aortic valve therapy. Prog Cardiovasc Dis.2014; 56: 635–645.
WebbJ.G., DoshiD., MackM.J.A randomized evaluation of the SAPIEN XT transcatheter heart valve system in patients with aortic stenosis who are not candidates for surgery. JACC Cardiovasc Interv.2015; 8: 1797–1806.
30.
BlumensteinJ., LiebetrauC., Van LindenA., MoellmannH., WaltherT., KempfertJ.Recent advances in transcatheter aortic valve implantation: novel devices and potential shortcomings. Curr Cardiol Rev.2013; 9: 274–280.
31.
RibeiroH.B., UrenaM., KuckK.H., WebbJ.G., Rodés-CabauJ.Edwards CENTERA valve. EuroIntervention: Journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.2012; 8(Suppl Q): Q79–Q82.
32.
SinningJ.M., WernerN., NickenigG., GrubeE.Medtronic CoreValve Evolut valve. EuroIntervention: Journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.2012; 8(Suppl Q): Q94–Q96.
33.
ChieffoA., BuchananG.L., Van MieghemN.M.Transcatheter aortic valve implantation with the Edwards SAPIEN versus the Medtronic CoreValve Revalving system devices: a multicenter collaborative study: the PRAGMATIC Plus Initiative (Pooled-RotterdAm-Milano-Toulouse In Collaboration). J Am Coll Cardiol.2013; 61: 830–836.
34.
ZahnR., GerckensU., GrubeE.Transcatheter aortic valve implantation: first results from a multi-centre real-world registry. Eur Heart J.2011; 32: 198–204.
35.
TreedeH., MohrF.W., BaldusS.Transapical transcatheter aortic valve implantation using the JenaValve&trademark; system: acute and 30-day results of the multicentre CE-mark study. Eur J Cardiothorac Surg.2012; 41: e131–e138.
36.
SchoferJ., ColomboA., KlugmannS.Prospective multicenter evaluation of the direct flow medical transcatheter aortic valve. Am Coll Cardiol.2014; 63: 763–768.
37.
MeredithI.T., WorthleyS.G., WhitbournR.J.Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: the REPRISE I study. EuroIntervention.2014; 9: 1264–1270.
38.
Meredith AmI.T., WaltersD.L., DumonteilN.Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study. J Am Coll Cardiol.2014; 64: 1339–1348.
39.
ZembalaM.O., PiegzaJ., WaclawskiJ.Symetis acurate transapical aortic valve: the initial experience with a second generation of transcatheter aortic valve replacement device. Kardiol Pol.2014; 72: 187–193.
40.
KempfertJ., HolzheyD., HofmannS.First registry results from the newly approved ACURATE TA&trademark; TAVI system†. Eur J Cardiothorac Surg.2015; 48: 137–141.
41.
MoellmannH.Results from the global registry: SAVI-TF. Conference presentation in EuroPCR 2016: Late breaking clinical trials, May 17, 2016, Paris, France. Available at: http://www.pcronline.com/Lectures/(speaker)/64706. Accessed September 19, 2016.
